JANX - Janux Therapeutics - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

JANX is currently covered by 7 analysts with an average price target of $69.87. This is a potential upside of $45.11 (182.19%) from yesterday's end of day stock price of $24.76.

Janux Therapeutics's activity chart (see below) currently has 7 price targets and 36 ratings on display. The stock rating distribution of JANX is 90% BUY and 10% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 53.23% with an average time for these price targets to be met of 270.71 days.

Highest price target for JANX is $200, Lowest price target is $62, average price target is $96.29.

Most recent stock forecast was given by SWAYAMPAKULA RAMAKANTH from HC WAINWRIGHT on 03-Mar-2025. First documented stock forecast 06-Jul-2021.

Currently out of the existing stock ratings of JANX, 27 are a BUY (90%), 3 are a HOLD (10%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$70

$46.2 (194.12%)

$70

3 months 2 days ago
(03-Mar-2025)

10/12 (83.33%)

$38.17 (119.92%)

252

Buy

$200

$176.2 (740.34%)

$200

5 months 25 days ago
(11-Dec-2024)

1/7 (14.29%)

$136.55 (215.21%)

966

Hold

$62

$38.2 (160.50%)

$42

6 months 1 days ago
(04-Dec-2024)

3/3 (100%)

$-4.84 (-7.24%)

7

Buy

$115

$91.2 (383.19%)

$70

6 months 2 days ago
(03-Dec-2024)

0/2 (0%)

$55.14 (92.11%)

Buy

$105

$81.2 (341.18%)

$70

6 months 2 days ago
(03-Dec-2024)

0/2 (0%)

$45.14 (75.41%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is JANX (Janux Therapeutics) average time for price targets to be met?

On average it took 270.71 days on average for the stock forecasts to be realized with a an average price target met ratio 53.23

Which analyst has the current highest performing score on JANX (Janux Therapeutics) with a proven track record?

SWAYAMPAKULA RAMAKANTH

Which analyst has the current lower performing score on JANX (Janux Therapeutics) with a proven track record?

SOUMIT ROY

Which analyst has the most public recommendations on JANX (Janux Therapeutics)?

Swayampakula Ramakanth works at HC WAINWRIGHT and has 3 price targets and 5 ratings on JANX

Which analyst is the currently most bullish on JANX (Janux Therapeutics)?

Josh Schimmer with highest potential upside - $176.2

Which analyst is the currently most reserved on JANX (Janux Therapeutics)?

Geoff Meacham with lowest potential downside - $24.2

Janux Therapeutics in the News

Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights

Phase 1b expansion study initiated with JANX007 in taxane-naïve mCRPC patients Updated JANX007 data from Phase 1a dose escalation support initiation of Phase 1b dose expansion Enrollment ongoing for JANX007 and JANX008 Updates on JANX007 and JANX008 expected in the second half of 2025 $1.01 billion in cash, cash equivalents, and short-term investments at end...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?